As a clinical pharmacokineticist, Dr Stephanie Reuter Lange’s research portfolio broadly focusses on using pharmacological principles to inform the optimal use of medications. Appropriately, through this activity she works extensively with pharmaceutical industry and regulatory agencies in the development of new drug entities, as well as clinicians and pharmacists to improve the use of existing drugs for better management of patients in clinical practice. Her research philosophy is one of translation, specifically bridging the interface between foundational science and clinical practice, acting as a conduit between science, policy and the clinic.
About me
As a clinical pharmacokineticist, Dr Stephanie Reuter Lange’s research portfolio broadly focusses on using pharmacological principles to inform the optimal use of medications. Appropriately, through this activity she works extensively with pharmaceutical industry and regulatory agencies in the development of new drug entities, as well as clinicians and pharmacists to improve the use of existing drugs for better management of patients in clinical practice. Her research philosophy is one of translation, specifically bridging the interface between foundational science and clinical practice, acting as a conduit between science, policy and the clinic.
About me
President, Australasian Pharmaceutical Science Association
Scientific Reviewer, Bellberry Human Research Ethics Committee
About me
Doctor of Philosophy University of South Australia
Bachelor of Science (Honours) The University of Adelaide
Stephanie currently holds an NHMRC Australian Clinical Research Fellowship, which aims to address the medication issues associated with the sub-optimal use of anti-infective agents and develop rational, evidence-based guidelines for the appropriate prescription of these drugs in clinical practice. She has previously been awarded a prestigious Fulbright Visiting Research Scholarship to undertake research with world leaders in the field of PK/PD modelling at the State University of New York, using innovative techniques to inform the quality use of medicines.
Research
Excludes commercial-in-confidence projects.
Optimising Cancer Therapy through Development of Evidence-Based Dose Individualisation Strategies, Cancer Council SA Research Fellowship, 01/07/2020 - 31/12/2023
PK & PD biostatistical studies, TetraQ, 09/10/2014 - 31/12/2019
PK analysis research services for clinical study DTX-SPL8783, Starpharma, 04/07/2016 - 30/07/2019
Literature Review of International Biosimilar Medicines, Department of Health, 01/03/2016 - 30/06/2018
PK and PD research advice, Prana Biotechnology, 25/09/2014 - 31/12/2017
Improving the therapeutic use of anti-infective agents: Application of pharmacometrics for rational dosing regimen design, NHMRC - Early Career Fellowship, 13/05/2013 - 12/05/2017
A potential diagnostic test for CFS, ANZ Trustees, 12/12/2011 - 24/12/2015
Research
Research since 2008 is shown below. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
| Year | Output |
|---|---|
| 2020 |
|
| 2020 |
|
| 2019 |
2
1
1
|
| 2019 |
1
1
|
| 2019 |
|
| 2019 |
Open access
1
|
| 2019 |
Open access
1
|
| 2019 |
|
| 2018 |
5
5
2
|
| 2016 |
Open access
19
18
6
|
| 2016 |
2
2
|
| 2015 |
Open access
13
13
1
|
| 2014 |
Open access
6
5
28
|
| 2014 |
Open access
11
11
2
|
| 2012 |
Open access
122
112
|
| 2012 |
1
1
4
|
| 2011 |
28
23
|
| 2011 |
Open access
18
13
4
|
| 2010 |
Open access
|
| 2009 |
Open access
27
27
|
| 2008 |
32
30
|
| 2008 |
21
20
|
| Year | Output |
|---|---|
| 2019 |
Open access
|
| 2019 |
Open access
|
| 2019 |
Open access
|
| 2018 |
Open access
|
| 2018 |
Open access
|
| 2018 |
Open access
|
| 2017 |
Open access
|
| 2017 |
Open access
|
| 2017 |
Open access
|
| 2017 |
Open access
|
| 2016 |
Open access
|
| 2016 |
Open access
|
| 2016 |
Open access
|
Research
Stephanie currently holds an NHMRC Australian Clinical Research Fellowship, which aims to address the medication issues associated with the sub-optimal use of anti-infective agents and develop rational, evidence-based guidelines for the appropriate prescription of these drugs in clinical practice. She has previously been awarded a prestigious Fulbright Visiting Research Scholarship to undertake research with world leaders in the field of PK/PD modelling at the State University of New York, using innovative techniques to inform the quality use of medicines.
Stephanie is a strong advocate for the importance of engagement and scientific communication to facilitate higher rates of research translation. She makes it a priority to engage end-users throughout the research process to maximise research outcomes and contribute significantly to health research within Australia and internationally. Stephanie also contributes widely to both the scientific and general communities through her involvement on a number of professional committees, dissemination of research findings to the public and promotion of careers in science. In acknowledgment of her scientific engagement and research significance, she has been awarded a Tall Poppy Award and two SA Science Excellence Awards.
External engagement & recognition
| Organisation | Country |
|---|---|
| Centre for Health Studies | LUXEMBOURG |
| CMAX | AUSTRALIA |
| Concord Repatriation General Hospital | AUSTRALIA |
| CPR Pharma Services Pty Ltd | AUSTRALIA |
| Drugs for Neglected Diseases initiative (DNDI) | SWITZERLAND |
| Hospital for Tropical Disease | THAILAND |
| Hunter Pathology | AUSTRALIA |
| Medicines for Malaria Venture | SWITZERLAND |
| Monash University | AUSTRALIA |
| Ohio State University | UNITED STATES |
| Pediatrix Screening | UNITED STATES |
| Princess Alexandra Hospital | AUSTRALIA |
| Royal Adelaide Hospital | AUSTRALIA |
| Royal North Shore Hospital | AUSTRALIA |
| Sigma-Tau Industrie Farmaceutiche Riunite | ITALY |
| St Vincent's Hospital | AUSTRALIA |
| Sydney Medical School | AUSTRALIA |
| Taylor's University | MALAYSIA |
| The University of Notre Dame Australia | AUSTRALIA |
| University of Groningen | NETHERLANDS |
| University of Newcastle | AUSTRALIA |
| University of Oxford | UNITED KINGDOM |
| University of Science, Malaysia | MALAYSIA |
| University of South Australia | AUSTRALIA |
| University of Sydney | AUSTRALIA |
| University of Wollongong | AUSTRALIA |
| Utrecht University | NETHERLANDS |
| Women's and Children's Hospital | AUSTRALIA |
| World Bank | UNITED STATES |
External engagement & recognition
| Engagement/recognition | Year |
|---|---|
Bellberry Human Research Ethics CommitteeBellberry Human Research Ethics Committee |
2017 |
PresidentAustralasian Pharmaceutical Science Association (APSA) |
2017 |
Finalist, Tall Poppy AwardAustralian Institute of Policy and Science |
2014 |
Peoples Choice, SA Science Excellence AwardsDepartment of State Development, Government of South Australia |
2014 |
Early Career FellowshipNational Health and Medical Research Council (NHMRC) |
2013 |
Fulbright Visiting Researcher ScholarshipAustralian-American Fulbright Commission |
2012 |
PhD Research Excellence Award, Health and Medical ScienceDepartment of State Development, Government of South Australia |
2012 |
As a research-focussed academic, Stephanie values the opportunity to contribute to undergraduate teaching of physiology and pharmacology. She recognises the importance of these core subjects and aims to produce students with a sound body of knowledge that forms the foundation of their subsequent learning. Stephanie also has an interest in the teaching of biostatistics, specifically removing the stigma associated with this complex topic and providing education in a manner that is more accessible and usable for all researchers.
Teaching & student supervision
Teaching & student supervision
Supervisions from 2010 shown
| Thesis title | Student status |
|---|---|
| A compartmental pharmacokinetic model for MaNac and sialic acid (Neu5Ac) in GNE Myopathy subjects | Current |
| Validate and optimization of Aminoglycoside Therapeutic Drug Monitoring in children and adults. | Current |
| Pharmacometric methodologies and their use for lenalidomide drug development in chronic lymphocytic leukaemia | Completed |
